Onilcamotide is a clinical-stage therapeutic cancer vaccine candidate targeting RhoC, an over-expressed protein in metastatic cancer cells. Onilcamotide is a peptide that forms a fragment of RhoC, and when introduced into the body, it triggers the immune system to attack the cells that overexpress RhoC.
"We have identified an interesting opportunity to exploit synergies between onilcamotide, our in-house DSM technology, and our already approved chemoembolization product EmboCept S. Through limited and responsible investments, we will now initiate activities with the aim to establish proof-of-concept for a reformulated version of onilcamotide. This constitutes an important first step in our long-term aim of bringing the drug candidate towards a potential marketing approval for a niche indication," says
CHOSA Oncology's CEO,
Under the licensing agreement, which covers onilcamotide and related intellectual properties,
This disclosure contains information that
For additional information contact:
Peter@chosa.bio
+ 45 21 60 89 22
justin.pierce@maglechemoswed.com
+46 (0)70 593 58 21
About
CHOSA in short
About iCIP™
CHOSA is focused on late-stage clinical development of iCIP™ (LiPlaCis® and its DRP® companion diagnostic together) to which it has worldwide rights. The cisplatin DRP is the only proven test to foresee and thereby select who to treat and who will benefit from cisplatin. The cisplatin DRP has previously shown its ability to foresee the value of cisplatin therapy in lung cancer. Even when lung cancer surgery is successful in removing all visible tumor, too many patients have a re-emergence of cancer. Cisplatin therapy after surgery is a gold standard that clearly increases lung cancer cure, but not always, and until now the doctors do not know who will benefit from cisplatin and who should have something else. This is where the cisplatin DRP is a potential game changer. Cisplatin DRP was validated in a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery to kill remaining tumor cells. Tissue from the patient's lung cancers was tested with the cisplatin DRP technology to get the DRP scores. A high cisplatin DRP score was directly linked to high cisplatin efficacy. Thus, patients with the 10% highest scores had a 3-year survival of 90% whereas the patients with the lowest 10% score had much lower survival with only 40% surviving 3 years1.
1) Buhl et al PLOS One doi: 10.1371/journal.pone0194609
DRP® is a registered trademark of
LiPlaCis is in-licensed from
https://news.cision.com/chosa-oncology-ab/r/chosa-oncology-ab-out-license-clinical-stage-cancer-vaccine-candidate-to-magle-group,c3767788
https://mb.cision.com/Main/13747/3767788/2063330.pdf
(c) 2023 Cision. All rights reserved., source